ProSciento's clinical trial site network and the number of specialty methods and imaging hubs in that region is growing steadily. Data from studies conducted in Australia can be used to support international regulatory applications, including the US FDA and European Medicines Evaluation Agency (EMEA), and the Australian government offers R&D tax incentives that make it a cost-effective location to carry out clinical trials.

"For many of our clients, Australia is a requested location for early phase clinical trials, often as part of a global multi-site clinical study strategy. The proximity to Asia and the Indian sub-continent, with many of the emerging biopharma companies situated in those geographies, makes Australia an excellent location for organizations like ProSciento. We have found an extraordinary commitment to the highest scientific and operational quality standards and many centers with advanced metabolic research expertise, all of which are a natural fit with ProSciento's mission and vision. We're very pleased to be expanding our operations in that region to further serve our clients' needs globally," said Marcus Hompesch, M.D., ProSciento's chief executive officer.